DEAR DR. ROACH: I am a 70-year old woman with a prior history of asymptomatic atrial fibrillation (AFib). I’ve been in normal sinus rhythm since having two catheter ablations in 2018. I take Eliquis ...

Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of patency and device-related thrombus were ...

Results of the Embolic Protection in Patients with Atrial Fibrillation (PROTECT-AF) showed that in AF patients who were candidates for warfarin therapy, device closure of the LAA using the Watchman ...

The Amplatzer Amulet (Abbott) and first-generation Watchman 2.5 (Boston Scientific) devices provide relatively comparable results out to 3 years after left atrial appendage occlusion (LAAO), longer ...

Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

The WATCHMAN FLX Pro team (pictured here) has successfully completed 159 WATCHMAN procedures, and will now only use the updated WATCHMAN FLX Pro Device moving forward. (Courtesy Photo) Medical Center ...